- Home
- FISI vs LRMR Comparison
FISI vs LRMR Comparison
Compare FISI & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FISI | LRMR |
|---|---|---|
| Founded | 1817 | N/A |
| Country | United States | United States |
| Employees | 598 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 620.8M | 316.6M |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | FISI | LRMR |
|---|---|---|
| Price | $31.77 | $3.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $33.67 | $16.71 |
| AVG Volume (30 Days) | 136.6K | ★ 1.1M |
| Earning Date | 01-29-2026 | 11-05-2025 |
| Dividend Yield | ★ 4.02% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $116,735,000.00 | N/A |
| Revenue This Year | $124.17 | N/A |
| Revenue Next Year | $6.77 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.97 | $1.61 |
| 52 Week High | $33.00 | $5.37 |
Technical Indicators
Market Signals| Indicator | FISI | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 55.50 | 39.84 |
| Support Level | $30.66 | $3.34 |
| Resistance Level | $32.03 | $4.01 |
| Average True Range (ATR) | 0.64 | 0.25 |
| MACD | -0.22 | -0.04 |
| Stochastic Oscillator | 45.73 | 8.28 |
Price Performance
Historical ComparisonAbout FISI Financial Institutions Inc.
Financial Institutions Inc operates as a financial holding company, engages in the provision of a wide range of consumer and commercial banking services to individuals, municipalities, and businesses in Western and Central New York. It operates through one segment: The Banking segment which includes all of the company's retail and commercial banking operations.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.